SG11202002841PA - Semaglutide in medical therapy - Google Patents
Semaglutide in medical therapyInfo
- Publication number
- SG11202002841PA SG11202002841PA SG11202002841PA SG11202002841PA SG11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA SG 11202002841P A SG11202002841P A SG 11202002841PA
- Authority
- SG
- Singapore
- Prior art keywords
- semaglutide
- medical therapy
- therapy
- medical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002841PA true SG11202002841PA (en) | 2020-04-29 |
Family
ID=60083831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002841PA SG11202002841PA (en) | 2017-10-12 | 2018-10-10 | Semaglutide in medical therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12029779B2 (ja) |
| EP (1) | EP3694538A1 (ja) |
| JP (2) | JP7148605B2 (ja) |
| KR (1) | KR20200069316A (ja) |
| CN (1) | CN111212657A (ja) |
| AU (1) | AU2018348929A1 (ja) |
| BR (1) | BR112020006246A2 (ja) |
| CA (1) | CA3078652A1 (ja) |
| CL (1) | CL2020000812A1 (ja) |
| IL (1) | IL273470A (ja) |
| MA (1) | MA50358A (ja) |
| MX (1) | MX2020003049A (ja) |
| PH (1) | PH12020550185A1 (ja) |
| SG (1) | SG11202002841PA (ja) |
| TW (1) | TWI842681B (ja) |
| WO (1) | WO2019072941A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294521A (en) * | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
| WO2022212271A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
| WO2023238017A1 (en) * | 2022-06-08 | 2023-12-14 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1412384B1 (en) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| BR122019021416A2 (ja) | 2003-09-19 | 2019-12-21 | ||
| CN113304250A (zh) | 2003-11-20 | 2021-08-27 | 诺和诺德股份有限公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| KR101340354B1 (ko) | 2004-11-12 | 2013-12-11 | 노보 노르디스크 에이/에스 | 안정한 펩티드 제제 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| DK1937219T3 (en) | 2005-09-14 | 2016-02-15 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles |
| RU2409349C2 (ru) | 2006-04-14 | 2011-01-20 | Маннкайнд Корпорейшн | Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1) |
| EP2121897A4 (en) | 2007-03-20 | 2010-03-31 | Nippon Kayaku Kk | METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL |
| CN101842386A (zh) | 2007-09-05 | 2010-09-22 | 诺沃-诺迪斯克有限公司 | 截短的glp-1衍生物和它们的治疗用途 |
| ES2620610T3 (es) | 2008-12-10 | 2017-06-29 | Glaxosmithkline Llc | Composiciones farmacéuticas de albiglutide |
| CN106177958A (zh) | 2009-02-13 | 2016-12-07 | 勃林格殷格翰国际有限公司 | 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| CN104311657B (zh) | 2009-12-16 | 2020-12-08 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
| WO2011138421A1 (en) * | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| DK2651398T3 (en) | 2010-12-16 | 2018-03-12 | Novo Nordisk As | Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid |
| EP2654774A4 (en) | 2010-12-22 | 2015-07-01 | Marcadia Biotech Inc | METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS WITH GIP AND GLP-1 RECEPTOR ACTIVE PUCIDIDES ON GLUCAGON BASIS |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| CN103906528A (zh) | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
| CN104519902B (zh) * | 2012-05-08 | 2017-10-27 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
| EP3689365A1 (en) * | 2012-07-01 | 2020-08-05 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| PT2991671T (pt) * | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| MY197023A (en) | 2015-12-23 | 2023-05-22 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
-
2018
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt unknown
- 2018-10-10 AU AU2018348929A patent/AU2018348929A1/en active Pending
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh active Pending
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko not_active Application Discontinuation
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en active Search and Examination
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020114960A3 (ja) | 2022-02-11 |
| CN111212657A (zh) | 2020-05-29 |
| TW201914611A (zh) | 2019-04-16 |
| US20240316159A1 (en) | 2024-09-26 |
| EP3694538A1 (en) | 2020-08-19 |
| IL273470A (en) | 2020-05-31 |
| JP7148605B2 (ja) | 2022-10-05 |
| CL2020000812A1 (es) | 2020-08-14 |
| JP2022132414A (ja) | 2022-09-08 |
| TWI842681B (zh) | 2024-05-21 |
| JP2020536854A (ja) | 2020-12-17 |
| AU2018348929A1 (en) | 2020-05-07 |
| US12029779B2 (en) | 2024-07-09 |
| US20200237876A1 (en) | 2020-07-30 |
| BR112020006246A2 (pt) | 2021-03-30 |
| JP7475398B2 (ja) | 2024-04-26 |
| MA50358A (fr) | 2020-08-19 |
| RU2020114960A (ru) | 2021-10-28 |
| WO2019072941A1 (en) | 2019-04-18 |
| MX2020003049A (es) | 2020-07-27 |
| KR20200069316A (ko) | 2020-06-16 |
| CA3078652A1 (en) | 2019-04-18 |
| PH12020550185A1 (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260383B (en) | Low dose medication | |
| EP3723685C0 (en) | MEDICAL ASSOCIATION | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| IL260771B1 (en) | Catheter closure solution and catheter closure treatment | |
| HK1253237A1 (zh) | 三維身體矯正裝置 | |
| SG11201707816PA (en) | Patient interface and aspects thereof | |
| IL250990A0 (en) | Materials for human care | |
| SG10202010420TA (en) | Patient interface and aspects thereof | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| IL257173A (en) | New insulin histories and their medical uses | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| HUE054998T2 (hu) | Kombinációs terápiák emlõrák kezelésében való alkalmazásra | |
| IL290251A (en) | Combination for effective treatment of metastatic cancer in patients | |
| IL247969B (en) | A medicinal component for use in the treatment of infections | |
| IL258835B (en) | A medical device for tissue sensing and/or stimulation | |
| IL273470A (en) | Semaglutide in medical treatment | |
| GB201709840D0 (en) | Methods and medical uses | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| EP3723686C0 (en) | MEDICAL ASSOCIATION | |
| GB201513097D0 (en) | Medical implant | |
| PT3325478T (pt) | Novo composto terapêutico e a utilização em terapia | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201607594D0 (en) | Patient stimulation device | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| EP3727136C0 (en) | IMPLANTABLE MEDICAL DEVICE |